or Try an Advanced Search...

    Technical Analysis for GNLX - Genelux Corporation

    Grade Last Price % Change Price Change
    D 2.49 0.40% 0.01
    GNLX closed up 0.4 percent on Wednesday, November 20, 2024, on 1.22 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical GNLX trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Resistance Bearish 0.40%
    MACD Bearish Centerline Cross Bearish 0.40%
    Boomer Sell Setup Bearish Swing Setup 0.40%
    Stochastic Reached Oversold Weakness 0.40%
    Inside Day Range Contraction 0.40%
    Wide Bands Range Expansion 0.40%
    Oversold Stochastic Weakness 0.40%
    Older End-of-Day Signals for GNLX ...

       Recent Intraday Alerts

    Alert Time
    1.5x Volume Pace about 21 hours ago
    Down 2 % about 21 hours ago
    Down 1% about 21 hours ago
    Up 3% about 22 hours ago
    Up 2% about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    GNLX Chart by TradingView
    Basic chart:

    Profile

    Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Virotherapy Immunotherapies Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Oncolytic Virus Experimental Cancer Treatments Transgene Sa Treatment Of Ovarian Cancer Treatment Of Pancreatic Cancer

    Is GNLX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Genelux GAAP EPS of -$0.19 beats by $0.01
    Nov 15 These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts
    Nov 14 Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
    Nov 6 Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
    Oct 31 Genelux: H2 2025 PRROC Data Is A Major Inflection Point
    Oct 31 Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well
    Oct 29 Genelux started at buy by Guggenheim ahead of Olvi-vec data
    Oct 25 Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp
    Oct 23 Genelux doses first subject in Phase II trial of NSCLC treatment
    Oct 22 Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
    See more GNLX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.6
    52 Week Low 1.6
    Average Volume 163,779
    200-Day Moving Average 3.56
    50-Day Moving Average 2.65
    20-Day Moving Average 2.88
    10-Day Moving Average 2.75
    Average True Range 0.29
    RSI (14) 42.53
    ADX 28.16
    +DI 16.51
    -DI 16.68
    Chandelier Exit (Long, 3 ATRs) 2.64
    Chandelier Exit (Short, 3 ATRs) 3.19
    Upper Bollinger Bands 3.42
    Lower Bollinger Band 2.33
    Percent B (%b) 0.14
    BandWidth 37.84
    MACD Line -0.03
    MACD Signal Line 0.05
    MACD Histogram -0.0809
    Fundamentals Value
    Market Cap 66.53 Million
    Num Shares 26.7 Million
    EPS -1.06
    Price-to-Earnings (P/E) Ratio -2.35
    Price-to-Sales 1003.60
    Price-to-Book 10.42
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.77
    Resistance 3 (R3) 2.78 2.69 2.73
    Resistance 2 (R2) 2.69 2.62 2.69 2.71
    Resistance 1 (R1) 2.59 2.57 2.54 2.58 2.69
    Pivot Point 2.50 2.50 2.48 2.50 2.50
    Support 1 (S1) 2.40 2.43 2.36 2.40 2.29
    Support 2 (S2) 2.31 2.38 2.31 2.27
    Support 3 (S3) 2.21 2.31 2.25
    Support 4 (S4) 2.21